Literature DB >> 3279919

Ultrasound diagnosis of nephrocalcinosis in preterm infants.

N Woolfield1, R Haslam, G Le Quesne, H M Chambers, R Hogg, K Jureidini.   

Abstract

The incidence of nephrocalcinosis in very low birthweight (less than 1500 g) premature infants was assessed by ultrasound scan and analysis of urine. Three of 36 infants had nephrocalcinosis. All had been receiving long term frusemide for bronchopulmonary dysplasia with simultaneous fluid restriction. Urinary investigations showed no consistent findings in babies with nephrocalcinosis.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3279919      PMCID： PMC1779332          DOI： 10.1136/adc.63.1.86

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  The pharmacologic effects of furosemide therapy in the low-birth-weight infant.

Authors:  B S Ross; A Pollak; W Oh
Journal:  J Pediatr       Date:  1978-01       Impact factor: 4.406

2.  Renal calcifications: a complication of long-term furosemide therapy in preterm infants.

Authors:  K G Hufnagle; S N Khan; D Penn; A Cacciarelli; P Williams
Journal:  Pediatrics       Date:  1982-09       Impact factor: 7.124

3.  Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome.

Authors:  H W Seyberth; W Rascher; H Schweer; P G Kühl; O Mehls; K Schärer
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

4.  Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression.

Authors:  H Patriquin; P Robitaille
Journal:  AJR Am J Roentgenol       Date:  1986-06       Impact factor: 3.959

5.  Sonographic diagnosis of furosemide-induced nephrocalcinosis in newborn infants.

Authors:  D M Pearse; J V Kaude; J L Williams; D Bush; P G Wright
Journal:  J Ultrasound Med       Date:  1984-12       Impact factor: 2.153
  5 in total
  9 in total

Review 1.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Evaluation of long-term aggressive dietary management of chronic renal failure in children.

Authors:  K F Jureidini; R J Hogg; M J van Renen; T R Southwood; P H Henning; L Cobiac; L Daniels; S Harris
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

3.  Renal follow up of premature infants with and without perinatal indomethacin exposure.

Authors:  R Ojala; M Ala-Houhala; S Ahonen; A Harmoinen; V Turjanmaa; S Ikonen; O Tammela
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

Review 4.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

5.  Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition.

Authors:  B Hoppe; A Hesse; T Neuhaus; S Fanconi; I Forster; N Blau; E Leumann
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

6.  Furosemide-related renal calcifications in the premature infant. A longitudinal ultrasonographic study.

Authors:  G J Downing; J C Egelhoff; D K Daily; U Alon
Journal:  Pediatr Radiol       Date:  1991

Review 7.  Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review.

Authors:  Wesley Jackson; Genevieve Taylor; David Selewski; P Brian Smith; Sue Tolleson-Rinehart; Matthew M Laughon
Journal:  Matern Health Neonatol Perinatol       Date:  2018-11-19

Review 8.  Nephrocalcinosis in preterm neonates.

Authors:  Eveline A Schell-Feith; Joana E Kist-van Holthe; Albert J van der Heijden
Journal:  Pediatr Nephrol       Date:  2008-09-17       Impact factor: 3.714

9.  Development of an animal model of nephrocalcinosis via selective dietary sodium and chloride depletion.

Authors:  Shamir Tuchman; Laureano D Asico; Crisanto Escano; Daniel A Bobb; Patricio E Ray
Journal:  Pediatr Res       Date:  2012-11-22       Impact factor: 3.756
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.